Margaret Tempero

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer
    Margaret A Tempero
    Pancreas Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Cancer Res 19:538-40. 2013
  2. ncbi Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
    Margaret Tempero
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisadero St, B726, UC Box 1770, San Francisco, CA 94115, USA
    J Clin Oncol 21:3402-8. 2003
  3. ncbi Blinded by the light: molecular imaging in pancreatic adenocarcinoma
    Eric Collisson
    Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA
    Clin Cancer Res 17:203-5. 2011
  4. ncbi Pancreatic cancer treatment and research: an international expert panel discussion
    M A Tempero
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
    Ann Oncol 22:1500-6. 2011
  5. ncbi Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology
    Margaret Tempero
    UCSF Comprehensive Cancer Center
    J Natl Compr Canc Netw 5:998-1033. 2007
  6. ncbi Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma
    Debra Sudan
    Department of Surgery, University of Nebraska Medical Center, Omaha, USA
    Am J Transplant 2:774-9. 2002
  7. ncbi Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007

Collaborators

Detail Information

Publications7

  1. ncbi Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer
    Margaret A Tempero
    Pancreas Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Cancer Res 19:538-40. 2013
    ..Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection...
  2. ncbi Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
    Margaret Tempero
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisadero St, B726, UC Box 1770, San Francisco, CA 94115, USA
    J Clin Oncol 21:3402-8. 2003
    ..To conduct a randomized phase II trial of dose-intense gemcitabine using a standard 30-minute infusion or the fixed dose rate (FDR) infusion (10 mg/m2/min) in patients with pancreatic adenocarcinoma...
  3. ncbi Blinded by the light: molecular imaging in pancreatic adenocarcinoma
    Eric Collisson
    Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA
    Clin Cancer Res 17:203-5. 2011
    ..Molecular imaging techniques may be the conduit through which new genomic and proteomic discoveries about this disease are brought to the clinic...
  4. ncbi Pancreatic cancer treatment and research: an international expert panel discussion
    M A Tempero
    Division of Hematology Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94115, USA
    Ann Oncol 22:1500-6. 2011
    ..A collaborative effort is needed to advance research and improve treatment. An expert conference was conducted to elicit perspectives regarding the current treatment and future research of pancreatic cancer...
  5. ncbi Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology
    Margaret Tempero
    UCSF Comprehensive Cancer Center
    J Natl Compr Canc Netw 5:998-1033. 2007
  6. ncbi Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma
    Debra Sudan
    Department of Surgery, University of Nebraska Medical Center, Omaha, USA
    Am J Transplant 2:774-9. 2002
    ..Long-term, tumor-free survival was achieved in 45% of the transplanted patients. Complications of biliary catheter placement for brachytherapy were associated with poor outcome...
  7. ncbi Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007
    ..To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma...